Bioprocessing Summit Europe 2025
Barcelona, Spain
March 18–20, 2025
Join Genedata team at the 8th Annual Bioprocessing Summit Europe 2025 in Barcelona, Spain.
Don't miss the opportunity to see how Genedata solutions digitalize and automate R&D workflows of biotherapeutics and vaccines, including screening, engineering, expression, purification and analysis, cell line development, bioprocess optimization, MS- and NGS-based quality control, and clinical trial design.
To get more information about our software or to arrange a meeting, please contact info(at)genedata.com.
Recommended Posters
End-To-End Software Platform for Streamlined LC/MS-based Multi-Attribute Method (MAM) Implementation
Albert Van Wyk, Business Account Manager, Genedata
Track C5B: Analytical & Quality - Next-Generation Analytical Method - Stream #6
Date: Wednesday afternoon - Thursday | 19 - 20 March 2025
Location: #B12 POSTER SESSION B: Exhibit Hall
We present an integrated software solution that covers the entire MAM workflow, featuring extracted ion chromatogram (XIC) based quality monitoring, automated results review, and an enhanced new peak detection (NPD) component for a scalable end-to-end MAM implementation. We demonstrate that combining an untargeted peptide-mapping-based approach and a targeted XIC-based approach streamlined the accurate identification of new peaks and the efficient monitoring of critical quality attributes while reducing the number of false positives.
Enterprise MS Analytics Software Platform for Streamlined Development and Production of Emerging Therapeutic Modalities
Nino Nikolovski, Business Account Manager, Genedata
Track C5B: Analytical & Quality - Next-Generation Analytical Method - Stream #6
Date: Wednesday afternoon - Thursday | 19 - 20 March 2025
Location: #B11 POSTER SESSION B: Exhibit Hall
With Mass spectrometry (MS) becoming an analytical platform of choice throughout the biopharmaceutical lifecycle—from in-depth characterization in discovery and development to quality monitoring in manufacturing—a flexible enterprise MS data analysis platform is essential to manage the wide diversity of workflows and increasingly complex therapeutic modalities such as therapeutic proteins, multi-specifics, novel conjugates, oligonucleotides, and AAVs. The Genedata Expressionist® enterprise software platform offers a customizable and scalable solution for MS analytics that streamlines the development and production of emerging biotherapeutics and facilitates MS access to both expert and non-expert users.
Integrated Analysis of Assays Drives Early Developability Assessment of Antibodies
Alexandre Peter, Business Development Manager, Genedata
Track C6a: Process Modelling and Developability - Stream #7
Date: Tuesday – Wednesday morning | 18-19 March 2025
Location: #A12 - POSTER SESSION A: Exhibit Hall
Biotherapeutics are now a leading class of therapy, but their development comes with unique challenges. Crucial to their later success in the clinic is their developability, or the key biophysical and biochemical properties that make a candidate suitable. In the case of antibodies, these include, among others, thermal stability, aggregation propensity, and expression efficiency. Some developability properties can be predicted by in silico methods, but many others must be empirically tested using a battery of standardized bioassays. These developability assay panels are now being run on hundreds of antibodies in parallel at an early stage in development, to avoid costly late-stage failure of drug candidates. This scale of testing poses new analysis challenges, including processing of high throughput data and efficient candidate profiling using results from the complete panel. In this poster, we demonstrate how Genedata Screener enables large-scale early assessment of developability through automation of data analysis and integrated data management.
